A pilot study examining patient preference and satisfaction for ava®, a reusable electronic injection device to administer certolizumab pegol. (3rd May 2020)

• Record Type: Journal Article
• Authors: Pouls, Bart P. H.; Kristensen, Lars E.; Petersson, Marianne; van den Bemt, B. J. F.; Ballerini, Luca; Bruggraber, Richard; Karlen, Henrik; Mountian, Irina; van Bracht, Etienne; Wiegratz, Susanne; Jørgensen, Tanja S.
• Is Part Of: Expert opinion on drug delivery. Volume 17:Number 5(2020)
• Page Start: 705
• Page End: 711
• Publication Date: 2020-05-03
• Subjects: Anti-TNF -- spondyloarthritis -- psoriatic arthritis -- rheumatoid arthritis -- patient perspective; Drug delivery devices -- Periodicals; Drug delivery systems -- Periodicals; 615.605
• DOI: 10.1080/17425247.2020.1736552
• Languages: English
• ISSNs: 1742-5247

Abstract

ABSTRACT: Background: Anti-tumor necrosis factor (anti-TNF) adherence is suboptimal. ava®, a reusable electromechanical self-injection device (e-Device) developed for certolizumab pegol (CZP) administration, aims to overcome some barriers to increase adherence. This study evaluates patient experience of the e-Device and its training materials and determines patient device preference. Methods: CZP-treated patients were recruited from the Netherlands, Denmark and Sweden. Patients completed a pre-injection Assessment of Self-Injection (ASI) questionnaire investigating self-injection perception. After training, patients administered 3 consecutive self-injections using the e-Device, patient experience of each was assessed using the post-injection ASI. An additional questionnaire evaluated training materials. After Injection 3, patients indicated their preference: the e-Device or their previous device. Results: 59 patients participated; most rated the e-Device highly for satisfaction, self-confidence and ease of use. The (negative) feelings and pain and skin reactions domains had low ratings. Post-injection ASI domain scores were similar following each of the 3 e-Device injections. Training materials were rated highly (video: 8.4/10; step-by-step guide: 8.4/10). 57.1% (32/56) patients preferred the e-Device over their previous self-injection device. Conclusions: Patients were satisfied with the e-Device and most preferred it over other self-injection devices. By improving patient experience, the e-Device may help increase medication adherence.